Inhibitor Therapeutics, Inc. (INTI)

Inhibitor Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	16	16	36	56	13	21
Market Cap Growth	22.17%	-56.36%	-35.77%	333.55%	-37.25%	-6.51%
Enterprise Value	8	7	25	57	13	20
PE Ratio	-	-5.23	2.99	-180.04	-12.32	-7.63
PB Ratio	3.34	2.99	4.37	-15.59	-3.87	-8.20
P/FCF Ratio	-3.79	-5.86	3.09	-256.03	-15.77	-7.67
P/OCF Ratio	-3.79	-5.86	3.09	-256.03	-15.77	-7.67
EV/EBITDA Ratio	-1.21	-2.05	-37.56	-174.06	-12.31	-7.26
EV/FCF Ratio	-1.31	-2.58	2.10	-256.94	-15.80	-7.37
Debt / Equity Ratio	-0.65	-0.57	0.05	-0.06	-0.03	1.19
Debt / EBITDA Ratio	-	-	-0.62	-0.71	-0.09	-
Debt / FCF Ratio	-	-	0.04	-1.05	-0.12	-
Quick Ratio	49.29	13.29	17.61	0.05	0.18	1.86
Current Ratio	50.01	13.45	17.64	0.09	0.25	1.96
Interest Coverage	0	0	-28.32	-21.93	0	0
Return on Equity (ROE)	-68.37%	-57.27%	145.92%	8.66%	31.45%	107.41%
Return on Assets (ROA)	-40.69%	-33.81%	101.09%	-533.26%	-802.12%	-302.10%
Return on Capital (ROIC)	-76.54%	-64.44%	-7.52%	9.60%	32.45%	108.56%
Earnings Yield	-20.45%	-19.13%	33.39%	-0.56%	-8.12%	-13.11%
FCF Yield	-20.00%	-17.07%	32.39%	-0.39%	-6.34%	-13.04%
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.48%
Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-3.65%
Buyback Yield / Dilution	-0.17%	53.25%	2.25%	-1.16%	-0.40%	-0.17%
Total Shareholder Return	-0.17%	53.25%	2.25%	-1.16%	-0.40%	0.31%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.